Medical News Today
AstraZeneca's experimental drug, selumetinib, is the first targeted medication to show a significant clinical benefit for patients with melanoma of the eye (metastatic uveal melanoma), researchers from the Memorial Sloan-Kettering Cancer Center explained at the 49th annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago, Illinois.
http://www.medicalnewstoday.com/articles/261350.php
Full Story